12/2009 |
Series B |
|
$14.2M |
|
10/2007 |
Series A |
|
$0 |
Genentech
Google
Mohr Davidow Ventures
New Enterprise Associates
Stephens Investment Management
Wendi Murdoch
Genentech
Google
Mohr Davidow Ventures
New Enterprise Associates
Stephens Investment Management
Wendi Murdoch
|
9/2017 |
Series F |
|
$0 |
Sequoia Capital
Altimeter Capital
Casdin Capital
Euclidean Capital
Fidelity
G Squared
Nimble Ventures
Wallenberg Foundations
Sequoia Capital
Altimeter Capital
Casdin Capital
Euclidean Capital
Fidelity
G Squared
Nimble Ventures
Wallenberg Foundations
|
12/2012 |
Series D |
5 |
$50M |
Sergey Brin
New Enterprise Associates
MPM Capital
GV
Anne Wojcicki
Sergey Brin
New Enterprise Associates
MPM Capital
GV
Anne Wojcicki
|
6/2009 |
Series B |
3 |
$13.6M |
Sergey Brin
New Enterprise Associates
Google
Sergey Brin
New Enterprise Associates
Google
|
10/2018 |
Series F |
1 |
- |
Rancilio Cube
Rancilio Cube
|
12/2020 |
Series F |
4 |
$82.5M |
Pegasus Tech Ventures
Sequoia Capital
NewView Capital
ACE &a; Company
NewView Capital
Sequoia Capital
Pegasus Tech Ventures
Sequoia Capital
NewView Capital
ACE &a; Company
NewView Capital
Sequoia Capital
|
7/2018 |
Corporate Round |
1 |
$300M |
GlaxoSmithKline
GlaxoSmithKline
|
11/2010 |
Debt Financing |
|
- |
|
9/2017 |
Venture Round |
|
$250M |
Sequoia Capital
|
10/2016 |
Grant |
1 |
$1.7M |
National Institutes of Health
National Institutes of Health
|
3/2021 |
IPO |
|
$592M |
|
7/2018 |
Equity |
|
$300M |
GlaxoSmithKline
|
8/2017 |
Series F |
|
- |
|
4/2018 |
Secondary Market |
1 |
- |
10X Capital
10X Capital
|
7/2014 |
Grant |
1 |
$1.4M |
National Institutes of Health
National Institutes of Health
|
10/2015 |
Series E |
9 |
$115M |
Xfund
WuXi Healthcare Ventures
New Enterprise Associates
MPM Capital
Lauder Partners
Illumina Ventures
GV
EquityZen
Casdin Capital
Xfund
WuXi Healthcare Ventures
New Enterprise Associates
MPM Capital
Lauder Partners
Illumina Ventures
GV
EquityZen
Casdin Capital
|
1/2019 |
Secondary Market |
2 |
- |
Raj Luhar
Future Planet Capital
Raj Luhar
Future Planet Capital
|
12/2020 |
Series F |
|
$82.5M |
Sequoia Capital
Xfund
|
1/2011 |
Series C |
2 |
$9M |
MPM Capital
Johnson &a; Johnson Development Corporation
MPM Capital
Johnson &a; Johnson Development Corporation
|
10/2017 |
Secondary Market |
3 |
- |
SharesPost Investment Management
James Sowers
Employee Stock Option Fund
SharesPost Investment Management
James Sowers
Employee Stock Option Fund
|
11/2010 |
Series C |
3 |
$22.2M |
New Enterprise Associates
Johnson &a; Johnson Development Corporation
GV
New Enterprise Associates
Johnson &a; Johnson Development Corporation
GV
|
6/2021 |
Post-IPO Equity |
6 |
$250M |
Richard Branson
Altimeter Capital
Anne Wojcicki
Foresite Capital
Fidelity Management and Research Company
Casdin Capital
Richard Branson
Altimeter Capital
Anne Wojcicki
Foresite Capital
Fidelity Management and Research Company
Casdin Capital
|
1/2019 |
Secondary Market |
2 |
- |
|
10/2018 |
Series F |
1 |
- |
|
4/2018 |
Secondary Market |
1 |
- |
|
10/2017 |
Secondary Market |
3 |
- |
|
9/2017 |
Series F |
8 |
$250M |
Sequoia Capital
Sequoia Capital
|
8/2017 |
Series F |
|
- |
|